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A B S T R A C T   
Diabetic peripheral neuropathy (DPN) is one of the most prevalent chronic complications of diabetes mellitus 
with no effective treatment. We recently demonstrated that mesenchymal stromal cell (MSC)-derived exosomes 
(exo-naïve) alleviate neurovascular dysfunction and improve functional recovery. MicroRNA (miRNA), one of the 
exosomal cargos, downregulates inflammation-related genes, resulting in suppression of pro-inflammatory gene 
activation. In the present study, we developed engineered MSC-exosomes loaded with miR-146a (exo-146a) and 
compared the therapeutic effects of exo-146a with exo-naïve in diabetic (db/db) mice with DPN. Exo-146a 
possesses a high loading capacity, robust ability to accumulate in peripheral nerve tissues upon systemic 
administration, and evokes substantially enhanced therapeutic efficacy on neurological recovery compared with 
exo-naïve. Treatment of DPN in diabetic mice with exo-146a for two weeks significantly increased and decreased 
nerve conduction velocity, and thermal and mechanical stimuli threshold, respectively, whereas it took four 
weeks of exo-naive treatment to achieve these improvements. Compared with exo-naïve, exo-146a significantly 
suppressed the peripheral blood inflammatory monocytes and the activation of endothelial cells via inhibiting 
Toll-like receptor (TLR)-4/NF-κB signaling pathway. These data provide a proof-of-concept about both the 
feasibility and efficacy of the exosome-based gene therapy for DPN. The translation of this approach to the clinic 
has the potential to improve the prospects for people who suffer from DPN.   
1. Introduction 
Diabetic peripheral neuropathy (DPN) is a highly complex and 
prevalent disease (Pop-Busui et al., 2017). There are currently more than 
20 million Americans who have DPN secondary to pre-diabetes, Type I 
diabetes, or Type II diabetes (Juster-Switlyk and Smith, 2016). The 
development of DPN closely correlates with neuroinflammation and 
neurovascular dysfunction in the distal nerves (Hinder et al., 2018; Negi 
et al., 2011; Zhou and Zhou, 2014). Therapies targeting neuro-
inflammation appear to ameliorate nerve dysfunction in experimental 
DPN (Bierhaus and Nawroth, 2009; Cameron et al., 2005; Hinder et al., 
2018; Negi et al., 2010; Sharma et al., 2012; Zhou and Zhou, 2014). 
Exosomes are nanovesicles with a diameter ranging from ~30-100 
nm (Thery et al., 2002). They are secreted by most cell types and 
transported in almost all biological fluids. Exosomes function as natural 
vehicles of bioactive molecules and thereby mediate intercellular 
communication (Wang et al., 2020; Zhang et al., 2019). Mesenchymal 
stromal cell (MSC)-derived exosomes have been reported to suppress the 
inflammatory immune response and promote the survival and regener-
ation of injured tissue (Harrell et al., 2019). Our recent study revealed 
that MSC-derived exosomes alleviate neurovascular dysfunction and 
facilitate DPN repair primarily by suppression of pro-inflammatory 
genes (Fan et al., 2020). Bioactive molecule (e.g., mRNA, miRNAs, cy-
tokines, chemokines, immunomodulatory factors) cargos within MSC- 
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exosomes regulate phenotype, function, and homing of immune cells 
(Harrell et al., 2019; Phinney et al., 2015). Exosomal miRNAs alter gene 
expression profiles in their recipient cells, and thereby, influence 
physiological responses (Kalluri and LeBleu, 2020). MiR-146a is a well- 
known anti-inflammatory miRNA and is involved in the pathogenesis of 
DPN (Jia et al., 2016; Wang et al., 2014). Our prior study demonstrated 
that systemic administration of chemically engineered miR-146a mimics 
encapsulated within liposomes substantially improves neurovascular 
function in diabetic mice (Liu et al., 2017). However, liposomes and 
polymeric nanoparticles have limitations concerning their biocompati-
bility and long-term safety for clinical use. Moreover, a high dose of 
oligos produces off-target effects, and the systemic utilization of miRNAs 
oligo in humans is very expensive and also not applicable for long-term 
inhibition due to their degradation and rapid dilution. To date, none of 
the miRNA-based therapies has reached the pharmaceutical break-
through in clinical trials. The therapeutic miRNAs exhibit low serum 
stability, off-targeting, and immune responses that hamper their clinical 
usage (Chakraborty et al., 2017). 
Exosome membranes shield their cargos from enzymatic degradation 
and contain recognition factors that allow them to target recipient cells 
(Yeo et al., 2013). Emerging reports have shown that exosomes are an 
efficient vehicle for nucleic acid therapies (Yeo et al., 2013). In contrast 
to synthetic drug delivery vehicles, the exosome-based delivery system 
has several advantages, including low immunogenicity, low toxicity, 
and high nucleic acid loading capacity. Therefore, they hold great 
promise as vehicles for therapeutic cargo (Escudier et al., 2005). 
In the present study, we utilized exosomes released by MSCs as 
biocompatible nanocarriers for systemic delivery of miR-146a and 
investigated if engineered MSC-exos enriched with miR-146a augment 
the therapeutic efficacy of MSC-exos and further improve neurovascular 
function, as well as the underlying mechanism of action of miR-146a 
engineered exosomes. These findings provide a rationale for the appli-
cation of engineered exosomes enriched with miR-146a for the clinical 
treatment of DPN. 
2. Methods 
2.1. Construction of engineered MSC-exosome carrying miR-146a (exo- 
146a) 
Mouse bone marrow-derived mesenchymal stromal cells (BM-MSCs, 
purchased from Thermo Fisher Scientific, Waltham, MA, USA) were 
transfected with XMIR-146a oligo (SBI System Biosciences, Palo Alto, 
CA, USA). Briefly, MSCs were seeded in 6-well plate and cultured in D- 
MEM/F-12 medium containing 5% exosome-depleted FBS (Thermo 
Fisher Scientific) to 80% confluency. 2 μg XMIR-146a oligo and 7.5 μL 
lipofectamine 2000 (Thermo Fisher Scientific) were diluted in 250 μL 
Opti-MEM™ Medium (Thermo Fisher Scientific), respectively before 
mixture. The DNA-lipid complex was incubated for 15 min at room 
temperature and added to MSCs for 4 h. The transfection mixture was 
then removed and added to the exosome-free culture medium. Twenty- 
four hours post-transfection, the medium was collected, centrifuged at 
10,000g for 10 min at 4 ◦C to remove cellular debris, and used fresh or 
stored at − 80 ◦C. 
To explore the in vivo distribution of MSC-exosomes, we produced 
GFP-CD63 containing exosomes. Brifely, MSCs were seeded in six-well 
plates and transfected with 4 μg/well of purified pCMV6-GFP-CD63 
(pCMV6-GFP-CD63, OriGene Technologies Inc., Rockville, MD, USA) 
using lipofectamine 2000 (Thermo Fisher Scientific) for 4 h, then 
remove the transfection mixture and add to exosome-free culture 
medium. 
The cell culture medium containing exosomes was filtered through 
0.22-μm filters. Exosomes were isolated by ultracentrifugation (Beck-
man Coulter, Brea, CA, USA) at 100,000 g for 2 h at 4 ◦C (Fan et al., 
2020). The exosomes in the pellet were suspended in saline and quan-
tified using Nanosight system (NS300, Cambridge, UK). Western blot 
analysis was performed to detect common exosome markers. 
2.2. Animals 
All animal procedures were approved by the Institutional Animal 
Care and Use Committee (IACUC) of Henry Ford Hospital and conducted 
in strict accordance with NIH Guidelines for the Care and Use of Labo-
ratory Animals. Male BKS.Cg-m+/+Leprdb/J (db/db) mice were pur-
chased from Jackson Laboratories (Bar Harbor, ME, USA). Same aged 
heterozygote mice (dm) were used as the control. At the age of 20 weeks, 
db/db mice were randomly divided into the following groups according 
to a randomization scheme: saline (db/db + vehicle), naïve MSC- 
exosomes (db/db + exo-naïve), and exo-146a (db/db + exo-146a). N 
= 8 per group. Exo-naïve and exo-146a were injected via a tail vein once 
a week for four consecutive weeks. Db/db group and dm group were 
administrated with same volume of saline. Glycosylated hemoglobin 
(HbA1c), glucose (Glc), total cholesterol (TC), and triglyceride (TG) 
levels in blood were monitored weekly using Accu-check active test 
strips (Roche Diagnostics, Basel, Switzerland). Serum insulin was tested 
prior to and after exosome treatment using a mouse ELISA kit (Thermo 
Fisher Scientific) according to the manufacturer’s protocol. 
2.3. Mechanical and thermal sensitivity tests 
The plantar test was performed to examine the sensitivity of the mice 
to heat (Fan et al., 2020; Fan et al., 2018). Mice were acclimated for 20 
min on a glass surface. A thermal stimulation meter (IITC Life Science, 
Woodland Hills, CA, USA) was placed under the plantar of the left hind 
paw. The withdrawal latency in response to the radiant heat (heating 
intensity was set as 15%) was recorded. Each mouse was tested three 
times at 15 min intervals. Von Frey test was performed to examine 
tactile allodynia (Chaplan et al., 1994). 
2.4. Neurophysiological measurements 
Motor and sensory nerve conduction velocity (MCV, SCV) were 
examined using orthodromic recording methods (Fan et al., 2020). The 
electrodes were placed at the right knee and the right sciatic notch of 
mice under anesthesia. Single square wave current pulses were given by 
the stimulator (Model 2100, A-M Systems, Sequim, WA, USA). MCV and 
SCV were calculated according to published studies (Fan et al., 2018; 
Obrosova et al., 2007). 
2.5. Vasa nervorum blood flow 
Blood perfusion in plantar and sciatic nerve were measured using 
laser Doppler perfusion imager (LDPI) system (PeriCam PSI System, 
Perimed AB, USA) (Fan et al., 2020; Fan et al., 2018). The perfusion 
color scale was adjusted as 0–250 for plantar and 0–60 for sciatic nerve. 
The Perfusion Units (PU) in selected regions of interest (ROI) were 
recorded. Mean perfusion values were calculated within 1 min. 
2.6. Myelin sheath staining 
The sciatic nerves were processed and cut into 2-μm thick transverse 
sections as previously described (Fan et al., 2018; Liu et al., 2017). The 
sections were stained with 1% toluidine blue. The diameter of axons, 
and myelinated and unmyelinated fibers were measured. The g-ratio 
was calculated as axon diameter/fiber diameter. 
2.7. Immunohistochemistry 
Footpad samples were fixed in 4% paraformaldehyde and embedded 
in paraffin, then cut into sections (6 μm). The primary antibodies used 
were polyclonal rabbit anti-protein gene product 9.5 (PGP9.5, Milli-
poreSigma, Burlington, MA, USA) and CD68 (Bio-Rad Laboratories, 
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Hercules, CA, USA). Normal rabbit IgG (Abcam) was used as a negative 
control and followed by Cy3-conjugated secondary antibody (Abcam) 
incubation. The number of PGP 9.5-immunoreactive nerve fiber density 
was calculated as previously described (Fan et al., 2020; Liu et al., 
2017). One section was chosen every ten sections for a total of three 
cross-sections per animal, which were used for immunostaining. 
2.8. Flow cytometry 
Blood was collected and monocytes were isolated using Ficoll density 
gradient centrifugation (MilliporeSigma). The isolated monocytes were 
suspended in flow cytometry staining buffer (BD Biosciences) and 
incubated with fluorescence-conjugated antibodies for 30 min at 4 ◦C. 
After washing with staining buffer, all samples were resuspended in PBS. 
Flow cytometry was performed using an SH800 flow cytometer (Sony 
Biotechnology, San Jose, CA). Antibodies against the following mouse 
antigens were used: CD11b (PE, 1:100, eBioscience), Ly-6C (APC, 1:100, 
eBioscience). Three distinct subsets of monocyte were characterized 
based on Ly-6C expression level: Ly6C+(classical), Ly6Cint (intermedi-
ate), and Ly6C− (non-classical) monocytes. 
2.9. Quantitative real-time RT-PCR (qRT-PCR) 
To compare the content of miR-146a in exosomes, exo-naïve and exo- 
146a were lysed in trizol (Qiagen, Valencia, CA, USA). For in vivo miR- 
146a analysis, sciatic nerve and footpad tissues were dissected from db/ 
db mice treated with exo-naïve or exo-146a (n = 3 mice/group) and 
lysed in trizol. Total RNA in each sample was isolated using miReasy 
Mini Kit (Qiagen). Reverse transcription was performed using miRNA 
reverse transcription kit (Applied Biosystem). The program was set as 
16 ◦C 30 min, 42 ◦C 30 min and 85 ◦C 5 min. TaqMan® microRNA assays 
were performed on a ViiA™ 7 real-time PCR Instrument (Applied Bio-
system) using TaqMan Universal PCR Master Mix (Applied Biosystem). 
The program was set as 95 ◦C 10 min, followed by 95 ◦C 15 s and 60 ◦C 1 
min for 40 cycles. Each TaqMan assay was done in triplicate for each 
sample tested. Relative quantities were calculated as the endogenous 
control using the 2-ΔΔCt method with U6 snRNA as control (4,427,975, 
ID#000200, Applied Biosystem). Mmu-miR-146a-5p (4,427,975, 
ID#000468, Applied Biosystem). 
2.10. Cell culture 
Db/m and db/db mice at the age of 20 weeks were anesthetized and 
injected intraperitoneally with PBS (containing 5 mmol/l EDTA). Mac-
rophages were elicited and cultured in RPMI-1640 (Gibco, Thermo 
Fisher Scientific) supplemented with 10% FBS (Gibco) in 24 well plates 
(105 cells/well)(Arroyo et al., 2011). To test the effects of exo-naïve and 
exo-146a on polarization, macrophages were treated with/without 
exosomes at a concentration of 1 × 106 particles/ml for 48 h. Both cells 
and medium were collected for further analysis. 
To mimic the diabetes-like environment in vitro, human dermal 
microvascular endothelial cells (HMVECs, ATCC) were cultured with 25 
mM glucose for 48 h and then treated with/without exosomes at a 
concentration of 1 × 106 particles/ml for 48 h. Cells were washed with 
PBS and lysed with RIPA buffer for Western blot analysis. 
Quantification was performed from at least three independent 
experiments. 
2.11. Western blot analysis 
Sciatic nerve or footpad dissected from db/db mice treated with/ 
without exosomes were lysed with RIPA buffer containing 1% protein-
ase and centrifuged at 12,000 g for 15 min at 4 ◦C to remove debris. 
Protein concentration in supernatant was measured using BCA assay 
(Thermo Fisher Scientific). 30 μg of total protein from tissue or HMVEC 
sample was separated by SDS-PAGE and transferred to PVDF 
membranes. After being blocked with 3% BSA blocking buffer, the 
membranes were incubated with the following antibodies overnight at 
4 ◦C: anti-β-actin (1:2000, Abcam, Cambridge, United Kingdom), 
inducible nitric oxide synthase (iNOS, 1:1000, EMD Millipore), 
Arginase-1 (Arg-1, 1:200, Santa Cruz), Toll-like receptor 4 (TLR4, 1:200, 
Santa Cruz), MyD88 (1:1000, Abcam), NF-KB p65 (1:500, Abcam), 
interleukin 1 receptor associated kinase 1 (IRAK1, 1:200, Santa Cruz, 
Dallas, TX, USA), TNF receptor associated factor (TRAF6, 1:200, Santa 
Cruz), vascular cell adhesion molecule 1 (VCAM-1, 1:500, Abcam), 
intercellular adhesion molecule 1 (ICAM-1, 1:1000, Abcam), CD9 
(1:500, Abcam), CD63 (1:500, Abcam), Alix (1:500, Cell Signaling 
Technology, Danvers, MA, USA), HSP60 (1:500, Cell Signaling Tech-
nology), calreticulin (1:500, Cell Signaling Technology). The next day, 
the membranes were incubated with secondary antibodies for 2 h and 
washed. The signals were visualized using an enhanced ECL substrate 
(Thermo Fisher Scientific). Image J software was used to quantify the 
band intensity in Western blot images. 
2.12. Enzyme-linked immunosorbent assays (ELISA) 
ELISA (Thermo Fisher Scientific) was used to quantify TNFα and IL- 
1β concentrations in the supernatant of cell culture according to the 
manufacturer’s protocol. 
2.13. Statistical analysis 
Data are presented as mean ± standard deviation (SD). Non- 
parametric one-way analysis of variance (ANOVA) followed by 
Tukey’s post hoc test was performed for multiple group comparisons. 
Two-tailed Student’s t-test was performed for two-group comparisons. A 
value of p < 0.05 was taken as significant. 
3. Results 
3.1. The therapeutic effect of exo-146a on DPN is superior to exo-naïve 
We first characterized exosomes isolated from the supernatant of 
MSCs transfected with XMIR-146a oligo and found that these exosomes 
termed as exo-146a had comparable size distribution with naïve MSC- 
exosomes (exo-naïve) assayed by Nanosight analysis (Fig. 1A). West-
ern blot analysis demonstrated that exo-146a contained CD9, CD63, and 
Alix proteins, but not endoplasmic reticulum markers-calreticulin or 
HSP60 (Fig. 1B). MiR-146a content within exo-146a was 102.5-fold 
higher than that in exo-naïve (Fig. 1C). These data indicate that exo- 
146a had the general characteristics of exosomes, but carried elevated 
levels of miR-146a. To examine exosome biodistribution, we first 
transfected MSCs with pCMV6-AC-GFP plasmid and then isolated the 
exosomes in the supernatant. We intravenously administered CD63- 
GFP/exosomes (109 particles/mouse) into db/db mice. Twenty-four 
hours later, the sciatic nerve was collected, fixed, and cut into paraffin 
sections. As shown in Fig. 1D, CD63-GFP was co-expressed with CD68 (a 
marker of macrophages) and CD31 (a marker of endothelial cells) sug-
gesting that MSC-exosomes were absorbed by macrophages and endo-
thelial cells, respectively, in peripheral nerve tissues. 
To examine the delivery capacity of exosomes in vivo, we adminis-
tered a one-time injection of exo-con and exo-146a (109 particles/ani-
mal) to db/db mice and collected sciatic nerve tissues 24 h later. The 
qRT-PCR data indicate that the miR-146a level in the sciatic nerve and 
footpad tissues were distinctly increased (Fig. 1E) and the expression of 
miR-146a target genes IRAK1 and TRAF6 were substantially decreased 
in mice treated with exo-146a compared with mice treated with exo-con 
(Fig. 1F-G). 
We recently reported that the treatment of DPN mice with exo-naïve 
for four weeks significantly improved peripheral nerve function (Fan 
et al., 2020). To examine the effect of exo-146a on DPN, db/db mice 
were treated with exo-146a or exo-naïve at the dose of 1 × 109 particles/ 
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injection once a week for four weeks via tail veins. As expected, 
compared with non-diabetic mice (dm), db/db mice exhibited DPN, as 
assayed employing MCV and SCV, plantar, and Von Frey tests before the 
treatment (Fig. 2A-D). Consistent with our previous finding, db/db mice 
treated with exo-naïve exhibited significant improvement of peripheral 
neurological function after four weeks of the treatment (Fig. 2A-D)(Fan 
et al., 2020). However, diabetic mice treated with exo-146a for two 
weeks exhibited significant increases of nerve conduction velocity 
(Fig. 2A-B), and reduced thermal and mechanical stimuli (Fig. 2C-D). At 
this time point, exo-naïve treated mice did not show obvious changes in 
nerve conduction or sensitivity. At week-4, both exo-naïve and exo-146a 
treated db/db mice showed improvement of peripheral neuronal func-
tion in the tests, and exo-146a treatment induced a more robust and 
significant effect than did exo-naïve treatment (Fig. 2A-D). These data 
indicate that the therapeutic effect of exo-146a on DPN is superior to 
exo-naïve. Neither of the exosomes affected the blood levels of glucose or 
lipid in db/db mice, suggesting the effects of exosomes were not medi-
ated through the alteration of glucose or lipid metabolism (Table. 1). 
Fig. 1. Engineered MSC-exosomes carry enriched miR-146a. A: Size distribution of exo-naïve and exo-146a were measured using the NanoSight system. B: 
Representative Western blot analysis for exosome markers and endoplasmic reticulum markers in exo-naïve and exo-146a. C: miR-146a expression levels in exo-naïve 
and exo-146a. D: Representative images of exo-146a (green) internalized by macrophages (CD68+, red) and endothelial cells (CD31+, red) in sciatic nerves. The 
nuclei were labeled with DAPI (blue), bar = 10 μm. E: Expression of miR-146a in sciatic nerve and plantar tissues. F-G: Representative images and quantification of 
Western blot analysis for miR-146a target genes IRAK1 and TRAF6 in sciatic nerve and plantar tissues of exo-naïve or exo-146a treated db/db mice. N = 3. ** p <
0.01 ***p < 0.001 exo-naïve vs exo-146a. 
Fig. 2. Exo-146a treatment restores the neurological outcomes db/db mice treated with exo-naïve or exo-146a once per week for 4 weeks. MCV (A) and SCV (B) were 
tested every two weeks. Threshold to thermal and mechanical stimuli in diabetic mice were by plantar test (C) and Von Frey test (D), respectively. Among the treated 
groups, exo-146a treated mice showed enhanced neurological outcomes after 2 weeks of administration. ##p < 0.01, ###p < 0.001 db/db + vehicle vs dm; ∆p < 0.05 
db/db + vehicle vs db/db + exo-naïve; *p < 0.05, **p < 0.01 db/db + vehicle vs db/db + exo-146a; ̂ p < 0.05 db/db + exo-naïve vs db/db + exo-146a. N = 8/group. 
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3.2. Exo-146a treatment induces a more robust improvement of 
neurovascular function in peripheral nerves than treatment with exo-naive 
In peripheral nerves, loss of axons, demyelination, and microvas-
cular dysfunction are related to DPN progression (Cameron et al., 2001; 
Doupis et al., 2009). Diabetic mice displayed a significant reduction in 
intraepidermal nerve fiber density (IENFD) in hind paw plantar skin 
compared with that in dm mice (Fig. 3A-B). Both exo-naïve and exo- 
146a treatments significantly increased IENFD; however, exo-146a 
treatment showed a more robust augmentation of IENFD (Fig. 3A-B). 
Exo-naïve and exo-146a significantly restored the diameter of nerve fi-
bers and promoted axon remyelination as well as considerably reduced g 
ratio as compared to the db/db group. In comparison with the same dose 
of exo-naïve, exo-146a treatment demonstrated a significantly greater 
impact on the axonal remyelination (Fig. 3C-E). Along with the devel-
opment of DPN, blood flow perfusion in plantar and sciatic nerves was 
significantly decreased in the db/db group compared with dm group. 
Treatment with exo-naïve for four weeks significantly retarded the 
suppressed blood perfusion flow. Importantly, we found that the treat-
ment of exo-146a further increased regional blood flow by 81% 
compared with the exo-naïve treated group (Fig. 3F-G). 
3.3. Exo-146a treatment induces pronounced immunosuppressive effects 
Infiltration of peripheral blood monocytes exacerbates DPN (Sun 
et al., 2019). Inflammatory monocytes are highly infiltrative and can 
differentiate into inflammatory macrophages, which cause neuro-
vascular damage (Yang et al., 2014). The peripheral blood collected 
from db/db mice compared with blood from dm mice contains an 
elevated level of inflammatory (classical) monocytes, while the admin-
istration of exo-naïve and exo-146a significantly decrease the percent-
age of classical monocytes (Fig. 4A-B). Compared with exo-naïve, exo- 
146a treatment exerted a more potent inhibitory inflammatory effect 
(Fig. 4A-B). 
We next investigated the effect of exo-146a treatment on macro-
phage polarization. Our data demonstrate that db/db mice showed 
significantly increased activated macrophage accumulation in sciatic 
nerves, measured by immunohistochemical staining against CD68+. The 
exo-146a treatment significantly reduced the number of CD68+ cells 
(Fig. 4C-D). In addition, exo-146a treatment significantly inhibits 
macrophage switching to the M1 phenotype characterized by iNOS and 
enhances the formation of the M2-like phenotype characterized by Arg-1 
(Fig. 4G-H). Moreover, treatment with exo-146a suppresses the secre-
tion of pro-inflammatory cytokines TNFα and IL-1β (Fig. 4E-F). We 
previously reported MSC-exos containing miRNAs synergistically 
downregulate the TLR4/NF-κB signaling pathway (Fan et al., 2020). 
Data from the present study reveal that miR-146a within exosomes 
inhibited its target gene IRAK1 and enhance the inhibition of TLR4, 
MyD88, and NF-κB expression. These data provide insight into why the 
effects of exo-146a on macrophages are more pronounced than those of 
exo-naïve (Fig. 4G-H). 
3.4. Exo-146a treatment amplifies the impact of exo-naïve on the 
attenuation of diabetes-induced endothelial dysfunction 
Hyperglycemia-induced activation of ECs increases inflammatory 
mediators, which enhance endothelial interactions with leukocytes and 
the sensitization of primary afferent neurons (De Caterina et al., 2000). 
We, therefore, examined whether exo-146a treatment modulates 
diabetes-induced activation of sciatic nerve endothelial cells. The 
expression of VCAM-1 and ICAM-1 were significantly increased in the 
sciatic nerves of db/db mice compared with dm mice. Exo-146a treat-
ment significantly reduced the levels of these proteins, while exo-naïve 
did not provide a pronounced effect on these adhesion molecules 
(Fig. 5A-B). 
Next, we examined whether exo-146a alters the inflammatory acti-
vation of HMVECs cultured in HG medium. Western blot analysis 
demonstrated that exo-146a showed a robust inhibitory effect on ICAM- 
1 and VCAM-1 expression (Fig. 5C-D). Both sets of exosomes inhibited 
HG-induced expression of TLR4, NF-κB, and TNFα, and exo-146a 
significantly reduced expression of these inflammatory mediators 
compared with exo-naïve (Fig. 5C-D). These findings highlight the 
protective roles of exo-146a on endothelial function and may at least 
partially explain its therapeutic effects on reducing neurovascular 
damage. 
4. Discussion 
In the present study, we employed engineered MSC-exosomes car-
rying enriched miR-146a (exo-146a) to treat db/db mice with DPN. In 
comparison to the treatment with exosomes isolated from naïve MSCs 
(exo-naïve), treatment with exo-146a amplifies and enhances the anti- 
inflammatory and protective effects on neurological function and pro-
motes neurorecovery in mice with DPN. Our data provide not only new 
insights into the molecular mechanisms of MSC-exosome therapy but 
also a proof-of-principle for MSC-exosomes to deliver a specific miRNA 
as cargo to the peripheral nervous system. 
Engineered exosomes are proposed as a biological nanoplatform for 
clinical drug delivery (van den Boorn et al., 2013). Compared with 
synthetic nanoscale particles, exosomes showed increased delivery and 
therapeutic efficacy because of their biocompatibility and the capacity 
to escape degradation (Luan et al., 2017; van der Meel et al., 2014; 
Zhang et al., 2019). Exosomes have natural targeting ability based on 
donor cells, and their size range allows them to easily penetrate deep 
tissue (Luan et al., 2017; Zhang et al., 2019). These favorable features 
drive efforts to engineer exosomes for the targeted delivery of exogenous 
nucleic acids and therapeutic drugs to target tissues (Mendt et al., 2018). 
MSC-derived exosomes have emerged as an attractive and safe experi-
mental application in the treatment of stroke, neural injury, neurode-
generative diseases, and cancer (Phinney and Pittenger, 2017; Xin et al., 
2013a; Xiong et al., 2017; Zhang et al., 2019). 
One of the widely used approaches for loading therapeutic genes into 
exosomes involves transfecting parent cells to overexpress the gene. Our 
group engineered miR-enriched MSC-exosomes for the treatment of 
stroke and observed that the miR cargo robustly enhanced the 
Table 1 
Concentration of blood glucose, lipids, insulin and body weight.  





























































































Values are mean ± SD.** p < 0.01, *** p < 0.001 db/db vs dm. n = 8/group. 
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therapeutic effect of naïve exosomes (Xin et al., 2017; Xin et al., 2013b; 
Zhang et al., 2017). These findings confirmed that engineered exosomes 
for miRNA delivery is feasible, practical and avoids the high cost and the 
potential adverse effects of using miRNA mimic the in vivo treatment. 
We previously reported that exo-naïve reduce the inflammatory 
response and thereby improved the neurological outcomes in db/db 
mice with DPN (Fan et al., 2020). To amplify their anti-inflammatory 
activity, we loaded miR-146a oligo into MSCs and produced miR-146a 
enriched exosomes. The transfection did not affect the basic properties 
of exosomes including marker expression and particle secretion. We 
showed that exo-146a is transferred to peripheral nerves and induces a 
relatively high level of miR-146a in target tissues. Our data also 
demonstrated the therapeutic effects of exo-146a are at least in part 
mediated via the regulation of diabetic chronic inflammation by regu-
lating miR-146 target genes, which indicates that the enriched miR-146a 
increases the immunomodulatory effects of naïve MSC-exosomes in 
DPN. Compared with exo-naïve, exo-146a shorten the therapy duration 
and achieved better recovery outcomes, indicating that the therapeutic 
effects of exo-146a are superior to those of exo-naïve. These findings add 
to the growing body of evidence that exosome-delivered miRNAs are 
part of the cell-cell communication network that coordinates immune 
responses. Although we do not exclude the possibility that the 
Fig. 3. Exo-146a treatment improves neurovascular perfusion and prevents the impairment in the peripheral nervous system. A-B: Representative immunofluo-
rescent images and quantification of PGP9.5 staining IENF in hind paw plantar skin of all groups. Bar = 50 μm. C: Semi-thin toluidine blue tained cross sections of 
sciatic nerves. Bar = 20 μm. D-E: Quantification of myelin thickness and g-ratio in sciatic nerve. F: Laser Doppler images of the planter and sciatic nerve of mice. Flux 
within tissues was measured and perfusion signal was expressed as different colors. Blood flow from low to high are marked as dark blue-green-yellow-red. G: 
Quantification of blood flow measurement results are expressed in Perfusion Units (PU)/ Regions of Interest (ROI). ###p < 0.001 db/db + vehicle vs dm; ∆p < 0.05 
db/db + vehicle vs db/db + exo-naïve; **p < 0.01 db/db + vehicle vs db/db + exo-146a; ^p < 0.05 db/db + exo-naïve vs db/db + exo-146a. N = 8/group. 
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transfection may have an impact on the exosome cargo, the observed 
therapeutic effect of exo-146a confirms the potential of MSC-exosomes 
as a miRNA vehicle for the treatment of DPN. Additional studies for 
the development the high scale and efficient production of clinical-grade 
exosomes are warranted. 
We and others previously reported the anti-inflammatory role of 
MSC-exosomes in a mouse model of DPN (Fan et al., 2020; Phinney 
et al., 2015; Zhang et al., 2014). Wiklander et al. reported that most of 
the injected MSC-derived extracellular vesicles accumulated in the 
mononuclear phagocyte system (Wiklander et al., 2015). The unbal-
anced monocyte phenotype in peripheral blood has an adverse impact 
on foot ulcer healing in diabetes patients (Mirza and Koh, 2011). In the 
present study, loading MSC-exosomes with miR-146a significantly 
augmented the effects of exo-naïve on the differentiation pattern of 
monocytes in peripheral blood. Furthermore, exo-146a provided more 
potent effects on the alteration of macrophage polarization and sup-
pressed the secretion of TNFα and IL-1β via inhibiting the TLR4/NF-κB 
pathway than exo- naïve. These data indicate that exo-146a inhibits 
inflammation by suppressing macrophage infiltration and M1 macro-
phage polarization in sciatic nerves, and decreases the production of 
cytokines that can activate the vascular endothelium and alter the sen-
sory transduction properties of axons, which in concert ameliorates 
DPN. It is noteworthy that the majority of exo-146a were detected in 
macrophages and endothelial cells of sciatic nerves. This may provide 
insight into the robust reduction of inflammation mediated by exo-146a. 
Further studies on the cell-specific internalization of MSC-exosomes are 
warrented. 
Chronic inflammation induces disruption of insulin signaling, lead-
ing to vascular complications in diabetes (Reddy et al., 2012; Shoelson 
et al., 2006). The anti-inflammatory miR-146a exerts protective effects 
on ECs in a mouse model of diabetic nephropathy (Bhatt et al., 2016; 
Huang et al., 2014). However, to our knowledge there have been no 
reports about the association of miR-146a with endothelial cell function 
in the progression of DPN. Our data demonstrate that exo-146a treat-
ment significantly reduces diabetes-induced expression of ICAM-1 and 
VCAM-1, while exo-naïve treatment did not show an obvious difference 
from control. Exo-146a reduces the synthesis of inflammatory cytokines 
by inhibiting the TLR4/NF-kB pathway, which at least partially explains 
the protective effects of exo-146a on peripheral nerve axons in db/db 
mice. Further studies are needed to investigate the effects of exo-146a on 
micro/macro vessel repair and the interaction of the affected vascula-
ture with leukocytes that may contribute to the reduction of blood vessel 
dysfunction in peripheral nerves resulting from exo-146a treatment of 
DPN. 
5. Conclusion 
In summary, our data demonstrate that exosomes as biologic vehicles 
of miR-146a can effectively mediate and enhance the therapeutic ac-
tivity of MSCs in diabetic mice, providing a novel therapeutic strategy 
Fig. 4. Effects of exo-146a treatment on inflammatory response. A–B: Monocyte subsets in the blood were characterized by CD11b and Ly6C staining. A: Repre-
sentative pattern plot of monocyte subsets in the peripheral blood of mice. B: Quantification of monocyte subsets. N = 8/group. C–D: Representative immunoflu-
orescent images and quantitative data of active macrophages (CD68+ cells) in sciatic nerve. E–F: Exo-naïve and exo-146a inhibited the secretion of TNFα and IL-1β in 
the supernatant from intraperitoneal macrophages cultures tested using ELISA. G–H: Representative images of Western blot analysis and the relative expression levels 
of iNOS, Arg-1, TLR4, MyD88, and NF-κB in macrophages. N = 3/group. ###p < 0.001 db/db + vehicle vs dm; ∆p < 0.05, ∆∆ p < 0.01 db/db + vehicle vs db/db +
exo-naïve; **p < 0.01, ***p < 0.001 db/db + vehicle vs db/db + exo-146a; ^p < 0.05, ^^p < 0.01 db/db + exo-naïve vs db/db + exo-146a. 
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for the benefit of neurovascular remodeling and functional recovery of 
DPN. This approach also provides a new platform that can be applied to 
other miRNAs that regulate the development of DPN. Although prom-
ising data are emerging, the possibility that MSC-exosomes may be 
employed in clinical use depends on the scaling of exosome production 
and the quality, reproducibility, and potency of the exosomes, which 
will require much effort. However, there is reason to believe that this 
cutting-edge technology will have great therapeutic potential for pa-
tients with DPN. 
Declaration of Competing Interest 
There are no conflicts of interest that relate to our manuscript. 
Acknowledgments 
We thank Julie Landschoot-Ward, Qinge Lu, and Sutapa Santra for 
the immunostaining. This study was supported by U.S. National In-
stitutes of Health (NIH) National Institute of Diabetes and Digestive and 
Kidney Diseases Grant RO1 (DK102861); American Heart Association 
Grant-in-Aid 14GRNT20460167. 
Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.expneurol.2021.113694. 
References 
Arroyo, J.D., Chevillet, J.R., Kroh, E.M., Ruf, I.K., Pritchard, C.C., Gibson, D.F., 
Mitchell, P.S., Bennett, C.F., Pogosova-Agadjanyan, E.L., Stirewalt, D.L., Tait, J.F., 
Tewari, M., 2011. Argonaute2 complexes carry a population of circulating 
microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U. S. A. 
108, 5003–5008. 
Bhatt, K., Lanting, L.L., Jia, Y., Yadav, S., Reddy, M.A., Magilnick, N., Boldin, M., 
Natarajan, R., 2016. Anti-inflammatory role of MicroRNA-146a in the pathogenesis 
of diabetic nephropathy. J. Am. Soc. Nephrol. 27, 2277–2288. 
Bierhaus, A., Nawroth, P.P., 2009. Multiple levels of regulation determine the role of the 
receptor for AGE (RAGE) as common soil in inflammation, immune responses and 
diabetes mellitus and its complications. Diabetologia 52, 2251–2263. 
Cameron, N.E., Eaton, S.E., Cotter, M.A., Tesfaye, S., 2001. Vascular factors and 
metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44, 
1973–1988. 
Cameron, N.E., Gibson, T.M., Nangle, M.R., Cotter, M.A., 2005. Inhibitors of advanced 
glycation end product formation and neurovascular dysfunction in experimental 
diabetes. Ann. N. Y. Acad. Sci. 1043, 784–792. 
Chakraborty, C., Sharma, A.R., Sharma, G., Doss, C.G.P., Lee, S.S., 2017. Therapeutic 
miRNA and siRNA: moving from bench to clinic as next generation medicine. Mol. 
Ther. Nucleic Acids 8, 132–143. 
Chaplan, S.R., Bach, F.W., Pogrel, J.W., Chung, J.M., Yaksh, T.L., 1994. Quantitative 
assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 53, 55–63. 
De Caterina, R., Liao, J.K., Libby, P., 2000. Fatty acid modulation of endothelial 
activation. Am. J. Clin. Nutr. 71, 213S–223S. 
Doupis, J., Lyons, T.E., Wu, S., Gnardellis, C., Dinh, T., Veves, A., 2009. Microvascular 
reactivity and inflammatory cytokines in painful and painless peripheral diabetic 
neuropathy. J. Clin. Endocrinol. Metab. 94, 2157–2163. 
Escudier, B., Dorval, T., Chaput, N., Andre, F., Caby, M.P., Novault, S., Flament, C., 
Leboulaire, C., Borg, C., Amigorena, S., Boccaccio, C., Bonnerot, C., Dhellin, O., 
Movassagh, M., Piperno, S., Robert, C., Serra, V., Valente, N., Le Pecq, J.B., Spatz, A., 
Lantz, O., Tursz, T., Angevin, E., Zitvogel, L., 2005. Vaccination of metastatic 
melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of 
thefirst phase I clinical trial. J. Transl. Med. 3, 10. 
Fan, B., Liu, X.S., Szalad, A., Wang, L., Zhang, R., Chopp, M., Zhang, Z.G., 2018. 
Influence of sex on cognition and peripheral neurovascular function in diabetic mice. 
Front. Neurosci. 12, 795. 
Fig. 5. Exo-146a treatment attenuates diabetes-induced activation of endothelial cells. A-B: Representative images of Western blot analysis and the relative 
expression levels of ICAM-1 and VCAM-1 in sciatic nerves of db/db mice with DPN. N = 3/group. ###p < 0.001 db/db + vehicle vs dm; ∆p < 0.05 db/db + vehicle vs 
db/db + exo-naïve; *p < 0.05 **p < 0.01 db/db + vehicle vs db/db + exo-146a; ^p < 0.05 db/db + exo-naïve vs db/db + exo-146a. C-D: Representative images of 
western blot analysis and the relative expression levels of ICAM-1, VCAM-1, TLR4, NF-κB and TNFα in HMVECs. N = 3/group. ### p < 0.001 HG + vehicle vs control; 
∆p < 0.05, ∆∆p < 0.01 HG + vehicle vs HG + exo-naïve; **p < 0.01, ***p < 0.001 HG + vehicle vs HG + exo-146a; ^p < 0.05, ^^p < 0.01 HG + exo-naïve vs HG +
exo-146a. 
B. Fan et al.                                                                                                                                                                                                                                      
Experimental Neurology 341 (2021) 113694
9
Fan, B., Li, C., Szalad, A., Wang, L., Pan, W., Zhang, R., Chopp, M., Zhang, Z.G., Liu, X.S., 
2020. Mesenchymal stromal cell-derived exosomes ameliorate peripheral 
neuropathy in a mouse model of diabetes. Diabetologia 63, 431–443. 
Harrell, C.R., Jovicic, N., Djonov, V., Arsenijevic, N., Volarevic, V., 2019. Mesenchymal 
stem cell-derived exosomes and other extracellular vesicles as new remedies in the 
therapy of inflammatory diseases. Cells 8. 
Hinder, L.M., Murdock, B.J., Park, M., Bender, D.E., O’Brien, P.D., Rumora, A.E., Hur, J., 
Feldman, E.L., 2018. Transcriptional networks of progressive diabetic peripheral 
neuropathy in the db/db mouse model of type 2 diabetes: an inflammatory story. 
Exp. Neurol. 305, 33–43. 
Huang, Y., Liu, Y., Li, L., Su, B., Yang, L., Fan, W., Yin, Q., Chen, L., Cui, T., Zhang, J., 
Lu, Y., Cheng, J., Fu, P., Liu, F., 2014. Involvement of inflammation-related miR-155 
and miR-146a in diabetic nephropathy: implications for glomerular endothelial 
injury. BMC Nephrol. 15, 142. 
Jia, L., Wang, L., Chopp, M., Zhang, Y., Szalad, A., Zhang, Z.G., 2016. MicroRNA 146a 
locally mediates distal axonal growth of dorsal root ganglia neurons under high 
glucose and sildenafil conditions. Neuroscience 329, 43–53. 
Juster-Switlyk, K., Smith, A.G., 2016. Updates in diabetic peripheral neuropathy. 
F1000Res 5. 
Kalluri, R., LeBleu, V.S., 2020. The biology, function, and biomedical applications of 
exosomes. Science 367. 
Liu, X.S., Fan, B., Szalad, A., Jia, L., Wang, L., Wang, X., Pan, W., Zhang, L., Zhang, R., 
Hu, J., Zhang, X.M., Chopp, M., Zhang, Z.G., 2017. MicroRNA-146a mimics reduce 
the peripheral neuropathy in type 2 diabetic mice. Diabetes 66, 3111–3121. 
Luan, X., Sansanaphongpricha, K., Myers, I., Chen, H., Yuan, H., Sun, D., 2017. 
Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta 
Pharmacol. Sin. 38, 754–763. 
Mendt, M., Kamerkar, S., Sugimoto, H., McAndrews, K.M., Wu, C.C., Gagea, M., Yang, S., 
Blanko, E.V.R., Peng, Q., Ma, X., Marszalek, J.R., Maitra, A., Yee, C., Rezvani, K., 
Shpall, E., LeBleu, V.S., Kalluri, R., 2018. Generation and testing of clinical-grade 
exosomes for pancreatic cancer. JCI Insight 3. 
Mirza, R., Koh, T.J., 2011. Dysregulation of monocyte/macrophage phenotype in 
wounds of diabetic mice. Cytokine 56, 256–264. 
Negi, G., Kumar, A., Kaundal, R.K., Gulati, A., Sharma, S.S., 2010. Functional and 
biochemical evidence indicating beneficial effect of Melatonin and Nicotinamide 
alone and in combination in experimental diabetic neuropathy. Neuropharmacology 
58, 585–592. 
Negi, G., Kumar, A., Sharma, S.S., 2011. Melatonin modulates neuroinflammation and 
oxidative stress in experimental diabetic neuropathy: effects on NF-kappaB and Nrf2 
cascades. J. Pineal Res. 50, 124–131. 
Obrosova, I.G., Ilnytska, O., Lyzogubov, V.V., Pavlov, I.A., Mashtalir, N., Nadler, J.L., 
Drel, V.R., 2007. High-fat diet induced neuropathy of pre-diabetes and obesity: 
effects of "healthy" diet and aldose reductase inhibition. Diabetes 56, 2598–2608. 
Phinney, D.G., Pittenger, M.F., 2017. Concise review: MSC-derived exosomes for cell-free 
therapy. Stem Cells 35, 851–858. 
Phinney, D.G., Di Giuseppe, M., Njah, J., Sala, E., Shiva, S., St Croix, C.M., Stolz, D.B., 
Watkins, S.C., Di, Y.P., Leikauf, G.D., Kolls, J., Riches, D.W., Deiuliis, G., 
Kaminski, N., Boregowda, S.V., McKenna, D.H., Ortiz, L.A., 2015. Mesenchymal stem 
cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs. Nat. 
Commun. 6, 8472. 
Pop-Busui, R., Boulton, A.J., Feldman, E.L., Bril, V., Freeman, R., Malik, R.A., Sosenko, J. 
M., Ziegler, D., 2017. Diabetic neuropathy: a position statement by the American 
Diabetes Association. Diabetes Care 40, 136–154. 
Reddy, M.A., Jin, W., Villeneuve, L., Wang, M., Lanting, L., Todorov, I., Kato, M., 
Natarajan, R., 2012. Pro-inflammatory role of microrna-200 in vascular smooth 
muscle cells from diabetic mice. Arterioscler. Thromb. Vasc. Biol. 32, 721–729. 
Sharma, A., Bernatchez, P.N., de Haan, J.B., 2012. Targeting endothelial dysfunction in 
vascular complications associated with diabetes. Int. J. Vasc. Med. 2012, 750126. 
Shoelson, S.E., Lee, J., Goldfine, A.B., 2006. Inflammation and insulin resistance. J. Clin. 
Invest. 116, 1793–1801. 
Sun, J.J., Tang, L., Zhao, X.P., Xu, J.M., Xiao, Y., Li, H., 2019. Infiltration of blood- 
derived macrophages contributes to the development of diabetic neuropathy. 
J Immunol Res 2019, 7597382. 
Thery, C., Zitvogel, L., Amigorena, S., 2002. Exosomes: composition, biogenesis and 
function. Nat. Rev. Immunol. 2, 569–579. 
van den Boorn, J.G., Dassler, J., Coch, C., Schlee, M., Hartmann, G., 2013. Exosomes as 
nucleic acid nanocarriers. Adv. Drug Deliv. Rev. 65, 331–335. 
van der Meel, R., Fens, M.H., Vader, P., van Solinge, W.W., Eniola-Adefeso, O., 
Schiffelers, R.M., 2014. Extracellular vesicles as drug delivery systems: lessons from 
the liposome field. J. Control. Release 195, 72–85. 
Wang, L., Chopp, M., Szalad, A., Zhang, Y., Wang, X., Zhang, R.L., Liu, X.S., Jia, L., 
Zhang, Z.G., 2014. The role of miR-146a in dorsal root ganglia neurons of 
experimental diabetic peripheral neuropathy. Neuroscience 259, 155–163. 
Wang, L., Chopp, M., Szalad, A., Lu, X., Zhang, Y., Wang, X., Cepparulo, P., Lu, M., Li, C., 
Zhang, Z.G., 2020. Exosomes derived from Schwann cells ameliorate peripheral 
neuropathy in type II diabetic mice. Diabetes 69, 749–759. 
Wiklander, O.P., Nordin, J.Z., O’Loughlin, A., Gustafsson, Y., Corso, G., Mager, I., 
Vader, P., Lee, Y., Sork, H., Seow, Y., Heldring, N., Alvarez-Erviti, L., Smith, C.I., Le 
Blanc, K., Macchiarini, P., Jungebluth, P., Wood, M.J., Andaloussi, S.E., 2015. 
Extracellular vesicle in vivo biodistribution is determined by cell source, route of 
administration and targeting. J. Extracell Vesicles 4, 26316. 
Xin, H., Li, Y., Cui, Y., Yang, J.J., Zhang, Z.G., Chopp, M., 2013a. Systemic 
administration of exosomes released from mesenchymal stromal cells promote 
functional recovery and neurovascular plasticity after stroke in rats. J. Cereb. Blood 
Flow Metab. 33, 1711–1715. 
Xin, H., Li, Y., Liu, Z., Wang, X., Shang, X., Cui, Y., Zhang, Z.G., Chopp, M., 2013b. MiR- 
133b promotes neural plasticity and functional recovery after treatment of stroke 
with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched 
extracellular particles. Stem Cells 31, 2737–2746. 
Xin, H., Katakowski, M., Wang, F., Qian, J.Y., Liu, X.S., Ali, M.M., Buller, B., Zhang, Z.G., 
Chopp, M., 2017. MicroRNA cluster miR-17-92 cluster in exosomes enhance 
neuroplasticity and functional recovery after stroke in rats. Stroke 48, 747–753. 
Xiong, Y., Mahmood, A., Chopp, M., 2017. Emerging potential of exosomes for treatment 
of traumatic brain injury. Neural Regen. Res. 12, 19–22. 
Yang, J., Zhang, L., Yu, C., Yang, X.F., Wang, H., 2014. Monocyte and macrophage 
differentiation: circulation inflammatory monocyte as biomarker for inflammatory 
diseases. Biomark. Res. 2, 1. 
Yeo, R.W., Lai, R.C., Zhang, B., Tan, S.S., Yin, Y., Teh, B.J., Lim, S.K., 2013. Mesenchymal 
stem cell: an efficient mass producer of exosomes for drug delivery. Adv. Drug Deliv. 
Rev. 65, 336–341. 
Zhang, B., Yin, Y., Lai, R.C., Tan, S.S., Choo, A.B., Lim, S.K., 2014. Mesenchymal stem 
cells secrete immunologically active exosomes. Stem Cells Dev. 23, 1233–1244. 
Zhang, Y., Chopp, M., Liu, X.S., Katakowski, M., Wang, X., Tian, X., Wu, D., Zhang, Z.G., 
2017. Exosomes derived from mesenchymal stromal cells promote axonal growth of 
cortical neurons. Mol. Neurobiol. 54, 2659–2673. 
Zhang, Z.G., Buller, B., Chopp, M., 2019. Exosomes - beyond stem cells for restorative 
therapy in stroke and neurological injury. Nat. Rev. Neurol. 15, 193–203. 
Zhou, J., Zhou, S., 2014. Inflammation: therapeutic targets for diabetic neuropathy. Mol. 
Neurobiol. 49, 536–546. 
B. Fan et al.                                                                                                                                                                                                                                      
